Table 1.
Characteristics of the survival analysis methods used to estimate the rmstD from IPD meta-analysis.
Fig 1.
Forest plot for differences in restricted mean survival time estimated using Pooled Kaplan-Meier (grey squares and diamond) and Pooled Exponential (dark green squares and diamond) applied to the MAR-LC dataset.
Each trial is represented by a square, the center of which denotes the difference in restricted mean survival time (rmstD) for that trial comparison, with the horizontal lines showing the 95% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The diamonds represent overall rmstDs, with the center denoting the rmstD and the extremities the 95% CI. CHART: Continuous Hyperfractionated Accelerated Radiation Therapy; CHARTWEL: CHART Week-End Less; CI: confidence interval; CT: chemotherapy; ECOG: Eastern Cooperative Oncology Group; Expo: Exponential; KM: Kaplan-Meier; MAR-LC: Meta-Analysis of Radiotherapy in Lung Cancer; NCCTG: North Central Cancer Treatment Group; PCMI: Peter MacCallum Institute; rmstD: difference in restricted mean survival time; RTOG: Radiation Therapy Oncology Group; RT: Radiotherapy.
Table 2.
Difference in restricted mean survival time and ICER according to the survival analysis method.
Fig 2.
Acceptability curves showing the probability that modified radiotherapy is cost-effective at different thresholds of willingness-to-pay for one life year.
Cost-effectiveness acceptability curves were derived from the 1,000 ICERs based on the bootstrap replicates to illustrate the uncertainty surrounding the cost-effectiveness of the experimental arm radiotherapy. Modified RT is considered cost-effective if the ICER is less than the willingness-to-pay for one life year. The acceptability curve represents the proportion of the replicates where modified RT is cost-effective for a range of different willingness-to-pay.